Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients
In a dedicated, double-blind, placebo-controlled ambulatory blood pressure study of patients with OAB, once-daily treatment with GEMTESA 75 mg was not associated with statistically significant or clinically meaningful effects on blood pressure or heart rate.
- In a dedicated, double-blind, placebo-controlled ambulatory blood pressure study of patients with OAB, once-daily treatment with GEMTESA 75 mg was not associated with statistically significant or clinically meaningful effects on blood pressure or heart rate.
- The article is entitled, Effects of Vibegron on Ambulatory Blood Pressure in Patients with Overactive Bladder: Results from a Double-Blind, Placebo-Controlled Trial.
- The published data substantiate that compared with placebo, GEMTESA has no statistically significant or clinically meaningful impact on blood pressure."
- The ambulatory blood pressure study enrolled 214 patients with OAB, aged between 40-75 years.